IBEX (IBEX) Q4 2026 Earnings Call Transcript
IBEX (IBEX) reported fiscal year 2026 revenue of $644.1 million, up 15.4%, with Q4 revenue at $164.3 million, up 11.6%. Adjusted EBITDA reached $82.4 million, a 14.5% increase. HealthTech revenue grew 38.5% to $114 million. Guidance for 2027 projects revenue of $700M-$715M and adjusted EBITDA of $90M-$94M. The company highlighted growth in AI-powered services and strategic partnerships.
How this was made
The 30-second read
Why it matters
The earnings beat and strong FY2027 guidance could trigger a short‑term price rally, while increased capex and offshore cost pressures warrant caution.
Market read
First‑report earnings with record financials and bullish guidance; high relevance for traders targeting AI‑enabled BPO stocks.
What to watch
Higher capital expenditures and potential regulatory scrutiny of AI agents could temper growth.
Background
IBEX (NASDAQ:IBEX) is a BPO provider expanding AI‑driven services across multiple verticals.
Ticker impact
IBEX reported record FY2026 revenue of $644.1M, adjusted EBITDA of $82.4M and issued FY2027 guidance of $700‑$715M revenue.
Potential price rally on the back of record results and bullish FY2027 outlook.
Revenue and EBITDA both hit new highs, guidance exceeds prior expectations, and share repurchases signal confidence.
Market effects
Highlights growth in HealthTech and AI‑enabled BPO services, potentially benefiting peers in the outsourcing sector.
Positive for U.S. tech and health‑care service providers.
Shows demand for AI‑driven BPO globally, may influence investor sentiment toward similar firms worldwide.
Counterpoint
Guidance may be overly optimistic given rising fuel costs and offshore margin pressure.
Key entities
- CEORobert T. Dechant
Provided commentary on AI partnership and growth outlook.
- CFOTaylor C. Greenwald
Discussed financial results and capital allocation.
